Global Alfacalcidol Market
Global Alfacalcidol Market

Alfacalcidol Comprehensive Study by Application (Pharmaceutical, Veterinary industry, Others), Form (Tablets, Injectables, Oral solutions, Soft gel capsules), Dosage route (Oral, Intravenous) Players and Region - Global Market Outlook to 2025

Alfacalcidol Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Jun 2020 Edition 231 Pages 213 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Scope of the Study

Alfacalcidol is an active metabolite of Vitamin D, that performs essential functions in regulation of the calcium balance as well as the bone metabolism. It is the Vitamin D-hormone analog that is activated by the enzyme 25-hydroxylase in the liver and osteoblasts for systemic and local D-hormone actions respectively. Moreover, Alfacalcidol is superior to plain vitamin D as the final kidney activation of the latter is regulated by a negative feedback mechanism. It is most commonly prescribed for patients with end stage renal disease.

The market study is being classified, by Application (Pharmaceutical, Veterinary industry and Others) and major geographies with country level break-up.

BOC Sciences (United States), Hydragon Pharma Ltd (China), Henan Tianfu Chemical Co., Ltd. (China), LGM Pharma (United States), Chemaphor Chemical Services (Canada), CARBOGEN AMCIS B.V. (Switzerland), Henan DaKen Chemical CO.,LTD. (China), Schwitz Biotech (India), Toronto Research Chemicals (Canada) and Hubei XinRunde Chemical Co., Ltd. (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Capot Chemical Co.,Ltd. (China), AdooQ BioScience, LLC (United States), Csc Pharmaceuticals International (United States), Pure Chemistry Scientific Inc. (United States) and Mainchem Co., Ltd. (China).

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Alfacalcidol market throughout the predicted period.

Segment Analysis
AdvanceMarketAnalytics has segmented the market of Global Alfacalcidol market by Type, Application and Region.

On the basis of geography, the market of Alfacalcidol has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Usage of Alfacalcidol is Fuelling the Market Growth
  • Rising Geriatric Population


Restraints
  • Availability of Alternative Products

Opportunities
  • Increasing Prevalence of Renal Disease
  • Increasing Investments by Governments

Challenges
  • Presence of Major Players is Leading to Market Growth





Key Target Audience
Manufacturers, Raw material suppliers, Government associations, Research organisations and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Application
  • Pharmaceutical
  • Veterinary industry
  • Others
By Form
  • Tablets
  • Injectables
  • Oral solutions
  • Soft gel capsules

By Dosage route
  • Oral
  • Intravenous

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Usage of Alfacalcidol is Fuelling the Market Growth
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Presence of Major Players is Leading to Market Growth
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Alfacalcidol, by Application, Form , Dosage route and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Alfacalcidol (Value)
      • 5.2.1. Global Alfacalcidol by: Application (Value)
        • 5.2.1.1. Pharmaceutical
        • 5.2.1.2. Veterinary industry
        • 5.2.1.3. Others
      • 5.2.2. Global Alfacalcidol Region
        • 5.2.2.1. South America
          • 5.2.2.1.1. Brazil
          • 5.2.2.1.2. Argentina
          • 5.2.2.1.3. Rest of South America
        • 5.2.2.2. Asia Pacific
          • 5.2.2.2.1. China
          • 5.2.2.2.2. Japan
          • 5.2.2.2.3. India
          • 5.2.2.2.4. South Korea
          • 5.2.2.2.5. Taiwan
          • 5.2.2.2.6. Australia
          • 5.2.2.2.7. Rest of Asia-Pacific
        • 5.2.2.3. Europe
          • 5.2.2.3.1. Germany
          • 5.2.2.3.2. France
          • 5.2.2.3.3. Italy
          • 5.2.2.3.4. United Kingdom
          • 5.2.2.3.5. Netherlands
          • 5.2.2.3.6. Rest of Europe
        • 5.2.2.4. MEA
          • 5.2.2.4.1. Middle East
          • 5.2.2.4.2. Africa
        • 5.2.2.5. North America
          • 5.2.2.5.1. United States
          • 5.2.2.5.2. Canada
          • 5.2.2.5.3. Mexico
  • 6. Alfacalcidol: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BOC Sciences (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Hydragon Pharma Ltd (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Henan Tianfu Chemical Co., Ltd. (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. LGM Pharma (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Chemaphor Chemical Services (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CARBOGEN AMCIS B.V. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Henan DaKen Chemical CO.,LTD. (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Schwitz Biotech (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Toronto Research Chemicals (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Hubei XinRunde Chemical Co., Ltd. (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Alfacalcidol Sale, by Application, Form , Dosage route and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Alfacalcidol (Value)
      • 7.2.1. Global Alfacalcidol by: Application (Value)
        • 7.2.1.1. Pharmaceutical
        • 7.2.1.2. Veterinary industry
        • 7.2.1.3. Others
      • 7.2.2. Global Alfacalcidol Region
        • 7.2.2.1. South America
          • 7.2.2.1.1. Brazil
          • 7.2.2.1.2. Argentina
          • 7.2.2.1.3. Rest of South America
        • 7.2.2.2. Asia Pacific
          • 7.2.2.2.1. China
          • 7.2.2.2.2. Japan
          • 7.2.2.2.3. India
          • 7.2.2.2.4. South Korea
          • 7.2.2.2.5. Taiwan
          • 7.2.2.2.6. Australia
          • 7.2.2.2.7. Rest of Asia-Pacific
        • 7.2.2.3. Europe
          • 7.2.2.3.1. Germany
          • 7.2.2.3.2. France
          • 7.2.2.3.3. Italy
          • 7.2.2.3.4. United Kingdom
          • 7.2.2.3.5. Netherlands
          • 7.2.2.3.6. Rest of Europe
        • 7.2.2.4. MEA
          • 7.2.2.4.1. Middle East
          • 7.2.2.4.2. Africa
        • 7.2.2.5. North America
          • 7.2.2.5.1. United States
          • 7.2.2.5.2. Canada
          • 7.2.2.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Alfacalcidol: by Application(USD Million)
  • Table 2. Alfacalcidol Pharmaceutical , by Region USD Million (2014-2019)
  • Table 3. Alfacalcidol Veterinary industry , by Region USD Million (2014-2019)
  • Table 4. Alfacalcidol Others , by Region USD Million (2014-2019)
  • Table 5. South America Alfacalcidol, by Country USD Million (2014-2019)
  • Table 6. South America Alfacalcidol, by Application USD Million (2014-2019)
  • Table 7. South America Alfacalcidol, by Form USD Million (2014-2019)
  • Table 8. South America Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 9. Brazil Alfacalcidol, by Application USD Million (2014-2019)
  • Table 10. Brazil Alfacalcidol, by Form USD Million (2014-2019)
  • Table 11. Brazil Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 12. Argentina Alfacalcidol, by Application USD Million (2014-2019)
  • Table 13. Argentina Alfacalcidol, by Form USD Million (2014-2019)
  • Table 14. Argentina Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 15. Rest of South America Alfacalcidol, by Application USD Million (2014-2019)
  • Table 16. Rest of South America Alfacalcidol, by Form USD Million (2014-2019)
  • Table 17. Rest of South America Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 18. Asia Pacific Alfacalcidol, by Country USD Million (2014-2019)
  • Table 19. Asia Pacific Alfacalcidol, by Application USD Million (2014-2019)
  • Table 20. Asia Pacific Alfacalcidol, by Form USD Million (2014-2019)
  • Table 21. Asia Pacific Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 22. China Alfacalcidol, by Application USD Million (2014-2019)
  • Table 23. China Alfacalcidol, by Form USD Million (2014-2019)
  • Table 24. China Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 25. Japan Alfacalcidol, by Application USD Million (2014-2019)
  • Table 26. Japan Alfacalcidol, by Form USD Million (2014-2019)
  • Table 27. Japan Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 28. India Alfacalcidol, by Application USD Million (2014-2019)
  • Table 29. India Alfacalcidol, by Form USD Million (2014-2019)
  • Table 30. India Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 31. South Korea Alfacalcidol, by Application USD Million (2014-2019)
  • Table 32. South Korea Alfacalcidol, by Form USD Million (2014-2019)
  • Table 33. South Korea Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 34. Taiwan Alfacalcidol, by Application USD Million (2014-2019)
  • Table 35. Taiwan Alfacalcidol, by Form USD Million (2014-2019)
  • Table 36. Taiwan Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 37. Australia Alfacalcidol, by Application USD Million (2014-2019)
  • Table 38. Australia Alfacalcidol, by Form USD Million (2014-2019)
  • Table 39. Australia Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 40. Rest of Asia-Pacific Alfacalcidol, by Application USD Million (2014-2019)
  • Table 41. Rest of Asia-Pacific Alfacalcidol, by Form USD Million (2014-2019)
  • Table 42. Rest of Asia-Pacific Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 43. Europe Alfacalcidol, by Country USD Million (2014-2019)
  • Table 44. Europe Alfacalcidol, by Application USD Million (2014-2019)
  • Table 45. Europe Alfacalcidol, by Form USD Million (2014-2019)
  • Table 46. Europe Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 47. Germany Alfacalcidol, by Application USD Million (2014-2019)
  • Table 48. Germany Alfacalcidol, by Form USD Million (2014-2019)
  • Table 49. Germany Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 50. France Alfacalcidol, by Application USD Million (2014-2019)
  • Table 51. France Alfacalcidol, by Form USD Million (2014-2019)
  • Table 52. France Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 53. Italy Alfacalcidol, by Application USD Million (2014-2019)
  • Table 54. Italy Alfacalcidol, by Form USD Million (2014-2019)
  • Table 55. Italy Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 56. United Kingdom Alfacalcidol, by Application USD Million (2014-2019)
  • Table 57. United Kingdom Alfacalcidol, by Form USD Million (2014-2019)
  • Table 58. United Kingdom Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 59. Netherlands Alfacalcidol, by Application USD Million (2014-2019)
  • Table 60. Netherlands Alfacalcidol, by Form USD Million (2014-2019)
  • Table 61. Netherlands Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 62. Rest of Europe Alfacalcidol, by Application USD Million (2014-2019)
  • Table 63. Rest of Europe Alfacalcidol, by Form USD Million (2014-2019)
  • Table 64. Rest of Europe Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 65. MEA Alfacalcidol, by Country USD Million (2014-2019)
  • Table 66. MEA Alfacalcidol, by Application USD Million (2014-2019)
  • Table 67. MEA Alfacalcidol, by Form USD Million (2014-2019)
  • Table 68. MEA Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 69. Middle East Alfacalcidol, by Application USD Million (2014-2019)
  • Table 70. Middle East Alfacalcidol, by Form USD Million (2014-2019)
  • Table 71. Middle East Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 72. Africa Alfacalcidol, by Application USD Million (2014-2019)
  • Table 73. Africa Alfacalcidol, by Form USD Million (2014-2019)
  • Table 74. Africa Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 75. North America Alfacalcidol, by Country USD Million (2014-2019)
  • Table 76. North America Alfacalcidol, by Application USD Million (2014-2019)
  • Table 77. North America Alfacalcidol, by Form USD Million (2014-2019)
  • Table 78. North America Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 79. United States Alfacalcidol, by Application USD Million (2014-2019)
  • Table 80. United States Alfacalcidol, by Form USD Million (2014-2019)
  • Table 81. United States Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 82. Canada Alfacalcidol, by Application USD Million (2014-2019)
  • Table 83. Canada Alfacalcidol, by Form USD Million (2014-2019)
  • Table 84. Canada Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 85. Mexico Alfacalcidol, by Application USD Million (2014-2019)
  • Table 86. Mexico Alfacalcidol, by Form USD Million (2014-2019)
  • Table 87. Mexico Alfacalcidol, by Dosage route USD Million (2014-2019)
  • Table 88. Company Basic Information, Sales Area and Its Competitors
  • Table 89. Company Basic Information, Sales Area and Its Competitors
  • Table 90. Company Basic Information, Sales Area and Its Competitors
  • Table 91. Company Basic Information, Sales Area and Its Competitors
  • Table 92. Company Basic Information, Sales Area and Its Competitors
  • Table 93. Company Basic Information, Sales Area and Its Competitors
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Alfacalcidol: by Application(USD Million)
  • Table 99. Alfacalcidol Pharmaceutical , by Region USD Million (2020-2025)
  • Table 100. Alfacalcidol Veterinary industry , by Region USD Million (2020-2025)
  • Table 101. Alfacalcidol Others , by Region USD Million (2020-2025)
  • Table 102. South America Alfacalcidol, by Country USD Million (2020-2025)
  • Table 103. South America Alfacalcidol, by Application USD Million (2020-2025)
  • Table 104. South America Alfacalcidol, by Form USD Million (2020-2025)
  • Table 105. South America Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 106. Brazil Alfacalcidol, by Application USD Million (2020-2025)
  • Table 107. Brazil Alfacalcidol, by Form USD Million (2020-2025)
  • Table 108. Brazil Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 109. Argentina Alfacalcidol, by Application USD Million (2020-2025)
  • Table 110. Argentina Alfacalcidol, by Form USD Million (2020-2025)
  • Table 111. Argentina Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 112. Rest of South America Alfacalcidol, by Application USD Million (2020-2025)
  • Table 113. Rest of South America Alfacalcidol, by Form USD Million (2020-2025)
  • Table 114. Rest of South America Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 115. Asia Pacific Alfacalcidol, by Country USD Million (2020-2025)
  • Table 116. Asia Pacific Alfacalcidol, by Application USD Million (2020-2025)
  • Table 117. Asia Pacific Alfacalcidol, by Form USD Million (2020-2025)
  • Table 118. Asia Pacific Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 119. China Alfacalcidol, by Application USD Million (2020-2025)
  • Table 120. China Alfacalcidol, by Form USD Million (2020-2025)
  • Table 121. China Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 122. Japan Alfacalcidol, by Application USD Million (2020-2025)
  • Table 123. Japan Alfacalcidol, by Form USD Million (2020-2025)
  • Table 124. Japan Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 125. India Alfacalcidol, by Application USD Million (2020-2025)
  • Table 126. India Alfacalcidol, by Form USD Million (2020-2025)
  • Table 127. India Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 128. South Korea Alfacalcidol, by Application USD Million (2020-2025)
  • Table 129. South Korea Alfacalcidol, by Form USD Million (2020-2025)
  • Table 130. South Korea Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 131. Taiwan Alfacalcidol, by Application USD Million (2020-2025)
  • Table 132. Taiwan Alfacalcidol, by Form USD Million (2020-2025)
  • Table 133. Taiwan Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 134. Australia Alfacalcidol, by Application USD Million (2020-2025)
  • Table 135. Australia Alfacalcidol, by Form USD Million (2020-2025)
  • Table 136. Australia Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 137. Rest of Asia-Pacific Alfacalcidol, by Application USD Million (2020-2025)
  • Table 138. Rest of Asia-Pacific Alfacalcidol, by Form USD Million (2020-2025)
  • Table 139. Rest of Asia-Pacific Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 140. Europe Alfacalcidol, by Country USD Million (2020-2025)
  • Table 141. Europe Alfacalcidol, by Application USD Million (2020-2025)
  • Table 142. Europe Alfacalcidol, by Form USD Million (2020-2025)
  • Table 143. Europe Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 144. Germany Alfacalcidol, by Application USD Million (2020-2025)
  • Table 145. Germany Alfacalcidol, by Form USD Million (2020-2025)
  • Table 146. Germany Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 147. France Alfacalcidol, by Application USD Million (2020-2025)
  • Table 148. France Alfacalcidol, by Form USD Million (2020-2025)
  • Table 149. France Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 150. Italy Alfacalcidol, by Application USD Million (2020-2025)
  • Table 151. Italy Alfacalcidol, by Form USD Million (2020-2025)
  • Table 152. Italy Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 153. United Kingdom Alfacalcidol, by Application USD Million (2020-2025)
  • Table 154. United Kingdom Alfacalcidol, by Form USD Million (2020-2025)
  • Table 155. United Kingdom Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 156. Netherlands Alfacalcidol, by Application USD Million (2020-2025)
  • Table 157. Netherlands Alfacalcidol, by Form USD Million (2020-2025)
  • Table 158. Netherlands Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 159. Rest of Europe Alfacalcidol, by Application USD Million (2020-2025)
  • Table 160. Rest of Europe Alfacalcidol, by Form USD Million (2020-2025)
  • Table 161. Rest of Europe Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 162. MEA Alfacalcidol, by Country USD Million (2020-2025)
  • Table 163. MEA Alfacalcidol, by Application USD Million (2020-2025)
  • Table 164. MEA Alfacalcidol, by Form USD Million (2020-2025)
  • Table 165. MEA Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 166. Middle East Alfacalcidol, by Application USD Million (2020-2025)
  • Table 167. Middle East Alfacalcidol, by Form USD Million (2020-2025)
  • Table 168. Middle East Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 169. Africa Alfacalcidol, by Application USD Million (2020-2025)
  • Table 170. Africa Alfacalcidol, by Form USD Million (2020-2025)
  • Table 171. Africa Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 172. North America Alfacalcidol, by Country USD Million (2020-2025)
  • Table 173. North America Alfacalcidol, by Application USD Million (2020-2025)
  • Table 174. North America Alfacalcidol, by Form USD Million (2020-2025)
  • Table 175. North America Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 176. United States Alfacalcidol, by Application USD Million (2020-2025)
  • Table 177. United States Alfacalcidol, by Form USD Million (2020-2025)
  • Table 178. United States Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 179. Canada Alfacalcidol, by Application USD Million (2020-2025)
  • Table 180. Canada Alfacalcidol, by Form USD Million (2020-2025)
  • Table 181. Canada Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 182. Mexico Alfacalcidol, by Application USD Million (2020-2025)
  • Table 183. Mexico Alfacalcidol, by Form USD Million (2020-2025)
  • Table 184. Mexico Alfacalcidol, by Dosage route USD Million (2020-2025)
  • Table 185. Research Programs/Design for This Report
  • Table 186. Key Data Information from Secondary Sources
  • Table 187. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Alfacalcidol: by Application USD Million (2014-2019)
  • Figure 5. South America Alfacalcidol Share (%), by Country
  • Figure 6. Asia Pacific Alfacalcidol Share (%), by Country
  • Figure 7. Europe Alfacalcidol Share (%), by Country
  • Figure 8. MEA Alfacalcidol Share (%), by Country
  • Figure 9. North America Alfacalcidol Share (%), by Country
  • Figure 10. Global Alfacalcidol share by Players 2019 (%)
  • Figure 11. Global Alfacalcidol share by Players (Top 3) 2019(%)
  • Figure 12. Global Alfacalcidol share by Players (Top 5) 2019(%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. BOC Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 15. BOC Sciences (United States) Revenue: by Geography 2019
  • Figure 16. Hydragon Pharma Ltd (China) Revenue, Net Income and Gross profit
  • Figure 17. Hydragon Pharma Ltd (China) Revenue: by Geography 2019
  • Figure 18. Henan Tianfu Chemical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 19. Henan Tianfu Chemical Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 20. LGM Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 21. LGM Pharma (United States) Revenue: by Geography 2019
  • Figure 22. Chemaphor Chemical Services (Canada) Revenue, Net Income and Gross profit
  • Figure 23. Chemaphor Chemical Services (Canada) Revenue: by Geography 2019
  • Figure 24. CARBOGEN AMCIS B.V. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. CARBOGEN AMCIS B.V. (Switzerland) Revenue: by Geography 2019
  • Figure 26. Henan DaKen Chemical CO.,LTD. (China) Revenue, Net Income and Gross profit
  • Figure 27. Henan DaKen Chemical CO.,LTD. (China) Revenue: by Geography 2019
  • Figure 28. Schwitz Biotech (India) Revenue, Net Income and Gross profit
  • Figure 29. Schwitz Biotech (India) Revenue: by Geography 2019
  • Figure 30. Toronto Research Chemicals (Canada) Revenue, Net Income and Gross profit
  • Figure 31. Toronto Research Chemicals (Canada) Revenue: by Geography 2019
  • Figure 32. Hubei XinRunde Chemical Co., Ltd. (China) Revenue, Net Income and Gross profit
  • Figure 33. Hubei XinRunde Chemical Co., Ltd. (China) Revenue: by Geography 2019
  • Figure 34. Global Alfacalcidol: by Application USD Million (2020-2025)
  • Figure 35. South America Alfacalcidol Share (%), by Country
  • Figure 36. Asia Pacific Alfacalcidol Share (%), by Country
  • Figure 37. Europe Alfacalcidol Share (%), by Country
  • Figure 38. MEA Alfacalcidol Share (%), by Country
  • Figure 39. North America Alfacalcidol Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • BOC Sciences (United States)
  • Hydragon Pharma Ltd (China)
  • Henan Tianfu Chemical Co., Ltd. (China)
  • LGM Pharma (United States)
  • Chemaphor Chemical Services (Canada)
  • CARBOGEN AMCIS B.V. (Switzerland)
  • Henan DaKen Chemical CO.,LTD. (China)
  • Schwitz Biotech (India)
  • Toronto Research Chemicals (Canada)
  • Hubei XinRunde Chemical Co., Ltd. (China)
Additional players considered in the study are as follows:
Capot Chemical Co.,Ltd. (China) , AdooQ BioScience, LLC (United States) , Csc Pharmaceuticals International (United States) , Pure Chemistry Scientific Inc. (United States) , Mainchem Co., Ltd. (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation